Mikael Dolsten Sells 634 Shares of Agilent Technologies (NYSE:A) Stock

Posted by Brian Himes on Sep 11th, 2026

Agilent Technologies, Inc. (NYSE:A – Get Free Report) Director Mikael Dolsten sold 634 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $151.38, for a total value of $95,974.92. Following the sale, the director directly owned 4,924 shares of the company’s stock, valued at $745,395.12. This represents a 11.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Agilent Technologies Price Performance

NYSE:A opened at $143.12 on Friday. Agilent Technologies, Inc. has a one year low of $108.35 and a one year high of $163.75. The company has a market cap of $40.35 billion, a P/E ratio of 28.17, a P/E/G ratio of 2.20 and a beta of 1.24. The firm’s fifty day moving average price is $143.38 and its two-hundred day moving average price is $128.49. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.05 and a quick ratio of 1.56.

Agilent Technologies (NYSE:A – Get Free Report) last posted its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. The company had revenue of $1.88 billion during the quarter, compared to analysts’ expectations of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. Agilent Technologies’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same quarter last year, the company posted $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Equities analysts expect that Agilent Technologies, Inc. will post 6.2 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on A shares. UBS Group assumed coverage on Agilent Technologies in a report on Wednesday. They set a “neutral” rating and a $165.00 price objective for the company. Robert W. Baird increased their target price on Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 26th. Bank of America lifted their price target on Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Sunday, August 2nd. Finally, Sanford C. Bernstein upped their price objective on Agilent Technologies from $155.00 to $180.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $170.33.

Get Our Latest Report on A

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in A. Bank of Nova Scotia acquired a new stake in shares of Agilent Technologies during the 2nd quarter worth approximately $58,539,000. Dudley & Shanley Inc. increased its stake in Agilent Technologies by 25.9% in the second quarter. Dudley & Shanley Inc. now owns 69,500 shares of the medical research company’s stock valued at $9,232,000 after acquiring an additional 14,300 shares during the last quarter. BIP Wealth LLC acquired a new position in Agilent Technologies during the second quarter valued at approximately $834,000. Capricorn Fund Managers Ltd bought a new stake in Agilent Technologies during the first quarter worth $8,161,000. Finally, KBC Group NV lifted its stake in Agilent Technologies by 18.4% during the second quarter. KBC Group NV now owns 81,883 shares of the medical research company’s stock worth $10,877,000 after purchasing an additional 12,719 shares during the last quarter.

Agilent Technologies News Summary

Here are the key news stories impacting Agilent Technologies this week:

Positive Sentiment: Agilent continues to outperform the Dow over the past 12 months, and Wall Street maintains a moderately bullish consensus. The company’s latest quarter exceeded expectations, with adjusted earnings of $1.62 per share versus the $1.49 consensus and revenue of $1.88 billion, up 8.1% year over year. Is Agilent Technologies Stock Outperforming the Dow?
Positive Sentiment: The stock has remained near its 52-week high following an increase in company guidance. Agilent currently expects fiscal 2026 earnings of approximately $6.18 to $6.21 per share, supporting the longer-term growth narrative. Agilent Technologies stock holds near 52-week high after guidance lift
Neutral Sentiment: Agilent will participate in the J.P. Morgan U.S. All Stars Conference. Investor attention may focus on management commentary regarding demand, laboratory spending and the company’s outlook, although no new financial information was announced. Agilent to Participate in J.P. Morgan U.S. All Stars Conference
Negative Sentiment: UBS initiated coverage with a Neutral rating and a $165 price target, lowering the stock’s previous Buy-rating momentum. The downgrade reflects valuation concerns despite the target implying further upside from recent trading levels. UBS Downgrades Agilent Technologies to Neutral From Buy
Negative Sentiment: Director Mikael Dolsten sold 634 shares for approximately $96,000, reducing his direct ownership by 11.4%. While relatively small compared with Agilent’s market value, the disclosed insider sale adds a modest negative signal. Agilent Technologies Director Sells 634 Shares

About Agilent Technologies

(Get Free Report)

Agilent Technologies, Inc is a global provider of analytical instruments, laboratory software, consumables and services used by organizations in the life sciences, diagnostics, pharmaceutical, chemical, environmental and food industries. Its solutions help customers analyze the composition and quality of substances, develop and manufacture products, and conduct research and testing.

The company’s offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic analysis equipment, automated electrophoresis systems, laboratory informatics software, columns and other consumables.